Hemo Organic Limited (HEMORGANIC) Fair Value & Analysis
Healthcare · IN · Market cap ₹73.2M
Fair value as of: Jul 5, 2026
From 1 valuation models · updated today
Share price +9.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹8.12 – ₹22.27 · fair‑value band ₹23.80 – ₹44.74 · the ₹21.11 price screens below the ₹36.18 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Hemo Organic Limited (HEMORGANIC) currently trades at ₹21.11, while our model-based Fair Value estimate is ₹36.18 — implying the stock looks roughly 71.4% undervalued today. We read business quality at 46/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Hemo Organic Limited generated revenue of ₹9.3M at a net margin of -83.6%. Revenue declined 62.7% year over year. Net debt stands at ₹27.3M. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹23.80 (bear case) to ₹44.74 (bull case); at ₹21.11, the current price sits below that range. The share trades about 6% below its 52-week high and 161% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -44% fair-value upside — at 71%, HEMORGANIC screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Hemo Organic Limited engages in the manufacture and sale of ayurvedik or Unani pharmaceutical preparations in India. It also engages in the manufacturing, trading, and dealing of chemicals, dyes, pigments, auxiliaries, intermediates, heavy and fine chemicals, organic and inorganic chemicals, etc. The company was formerly known as Dinesh Allorga Limited and changed its name to Hemo Organic Limited in August 2013. The company was incorporated in 1992 and is based in Anand, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Hemo Organic Limited reported revenue of ₹9.3M in FY2026 versus ₹68.3K in FY2022, a compound +241.5%/yr. Reported net income was −₹7.8M in FY2026.
Is HEMORGANIC fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,416 | ₹1,466 | +4% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,278 | ₹595.34 | -53% |
| PharmaEssentia Corporation 6446 | 1,095 TWD | 365.87 TWD | -67% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Hemo Organic Limited (HEMORGANIC) undervalued?
What is the fair value of HEMORGANIC?
What is the quality score of HEMORGANIC?
What is the revenue of Hemo Organic Limited (HEMORGANIC)?
What is the net profit margin of HEMORGANIC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.